UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO ~~SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~SECTION 13 ofOR ~~Report~~ 15(~~Date of earliest event reported~~D)~~: January~~ ~~15,~~OF ~~2017~~THE

~~21st~~SECURITIES ~~CENTURY~~EXCHANGE ~~ONCOLOGY~~ACT ~~HOLDINGS, INC.~~OF 1934

Date of Report (Date of earliest event reported): January 23, 2017

21st CENTURY ONCOLOGY

HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware ~~(State or Other Jurisdiction of Incorporation)~~

333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)
2270 Colonial Boulevard		33907
Fort Myers, Florida		(Zip Code)
(Address of Principal Executive Offices)

(State or Other Jurisdiction of Incorporation)

333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)

2270 Colonial Boulevard Fort Myers, Florida		33907
(Address of Principal Executive Offices)		(Zip Code)

(239) 931-7254
(Registrant’s Telephone Number, including Area Code)

N/A ~~(Former Name or Former Address, if Changed Since Last Report.)~~

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 15.0102 ~~Entry~~Departure ~~into~~of aDirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

AsOn ~~previously~~January 23, ~~disclosed~~2017, ~~on December~~Dr. 6,Daniel ~~2016~~E. Dosoretz, ~~21st~~a ~~Century~~member ~~Oncology~~of ~~Holdings, Inc.~~the ~~(“we,”~~Board ~~“our,”~~of ~~“us”~~Directors or (the “~~Company~~Board”), of 21st Century Oncology Holdings, Inc. (the “~~21C~~Company”), anotified ~~subsidiary of~~ the ~~Company,~~Board ~~and certain~~ of ~~the~~his ~~Company’s~~decision ~~other~~to ~~subsidiaries~~resign ~~entered~~as ~~into~~ a ~~Forbearance~~director ~~Agreement~~of ~~relating to~~ the Company’s, ~~indenture~~effective ~~and~~immediately. aThe ~~Forbearance Agreement relating to the~~ Company’s ~~credit~~thanks ~~agreement~~him ~~(collectively,~~for ~~the~~his ~~“Forbearance~~time ~~Agreements”),~~and ~~with~~dedicated ~~certain~~service ofon ~~21C’s~~the ~~noteholders~~Board. Dr. Dosoretz ~~and~~continues ~~lenders,~~to ~~respectively.~~serve ~~The~~as ~~Forbearance~~a ~~Agreements~~Senior ~~were~~Physician ~~subsequently~~for ~~amended~~the ~~on December 15~~Company, ~~2016.~~and Asthe ~~amended,~~Company ~~the~~looks ~~Forbearance~~forward ~~Agreements~~to ~~required,~~working ~~among~~with ~~other~~Dr. Dosoretz ~~things,~~and ~~that~~his ~~21C~~affiliates ~~enter~~to ~~into~~continue ato ~~transaction~~provide ~~support~~quality ~~agreement~~care ~~with~~to its ~~noteholders~~patients and ~~lenders~~grow ~~(as~~its ~~applicable)~~business nofor ~~later~~its ~~than~~extensive ~~January 4,~~physician ~~2017~~network ~~(the~~and ~~“TSA Deadline”)~~stakeholders.

OnForward-Looking January 15, 2017, we entered into amendments to the Forbearance Agreements (collectively, the “Amendments”) to, among other things, amend the TSA Deadline to January 31, 2017. The Forbearance Agreements, as amended by the Amendments, provide that the noteholders and lenders party thereto will forbear, subject to important exceptions, until the earlier of January 31, 2017 and the occurrence of certain events (as described in the Forbearance Agreements) from exercising any rights and remedies under 21C’s indenture, notes or credit agreement, as applicable, on account of certain events of default.Statements

InThis ~~addition,~~Current Report on ~~January~~Form ~~15,~~8-K ~~2017,~~contains ~~Medical~~forward-looking ~~Developers,~~statements ~~LLC,~~within anthe ~~indirect~~meaning ~~wholly~~of ~~owned~~Section 27A ~~subsidiary~~ of the ~~Company~~Securities Act and ~~certain~~Section 21E of ~~its~~the ~~affiliates,~~Exchange ~~entered~~Act. ~~into~~Forward-looking anstatements ~~amendment~~are based on management’s current expectations or beliefs. Readers of this Current Report on Form 8-K are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the ~~MDL~~date ~~Credit~~of ~~and~~this ~~Guarantee~~Current ~~Agreement~~Report on Form 8-K. The Company undertakes no obligation to ~~extend~~publicly update or revise the ~~maturity~~forward-looking statements contained herein to reflect changed events or circumstances after the date ~~from~~of ~~January 15,~~this ~~2017~~Current toReport ~~January 31,~~on ~~2017~~Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	21st CENTURY ONCOLOGY HOLDINGS, INC.
Date: January 17, 2017	By:	/s/ LeAnne M. Stewart
Date: January 26, 2017	By:	/s/ LeAnne M. Stewart
		Name:	LeAnne M. Stewart
		Name: LeAnne M. Stewart
		Title:	Chief Financial Officer
		Title: Chief Financial Officer

Filing Compare · 21st Century Oncology Holdings, Inc.